Fed. Circ. Again Eyes Ban On Lupin's Generic Fortamet

Law360, New York (April 17, 2012, 8:55 PM EDT) -- An order in a patent dispute barring Lupin Ltd. from selling its generic version of the diabetes drug Fortamet once again will be scrutinized by the Federal Circuit on Wednesday, two months after the appeals court lifted the same preliminary injunction.

The Federal Circuit, which vacated the injunction in February, will hear oral arguments in the appeal of a lower court's decision on remand to reinstate the order granted to plaintiff Shionogi Pharma Inc.

Judge Robert Kugler of the District of Delaware imposed the preliminary injunction...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.